Celal Ayaz
Research Subjects
Research Interests
Celal Ayaz has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Kemal Çelen
Infectious Diseases and Clinical Microbiology, Dicle University, Diyarbakir, Turkey, Turkey (Türkiye)
12 shared publications - Mehmet Ulug
Özel Ümit Hospital, Eskisehir, Turkey
7 shared publications - Tuba Dal
Medical Microbiology Department, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey
5 shared publications - Ercan Gedik
Dicle University Medical School, Diyarbakir, Turkey
4 shared publications Kadim Bayan
4 shared publications- Mehmet Faruk Geyik
Department of Infectious Diseases and Clinic Microbiology, Duzce University Medical School, Düzce, Turkey
4 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 70, S118-S119
The comparison of adefovir dipivoxil or combination with lamivudine in patients with lamivudine resistant chronic hepatitis B
- 1 September 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 70, S118-S119
The comparison of adefovir dipivoxil or combination with lamivudine in patients with lamivudine resistant chronic hepatitis B
- 1 September 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 70, S10
Two years therapy of chronic hepatitis delta with pegylated interferon-alpha-2a
- 1 September 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 70, S10
Two years therapy of chronic hepatitis delta with pegylated interferon-alpha-2a
- 1 March 2015
- Vol. 23 (1) , 31-5
Tenofovir disoproxil fumarate treatment in HbeAg-positive patients.
Tenofovir disoproxil fumarate (Tenofovir DF) is a nucleotide analogue. This multicentre study reports retrospectively the long-term efficacy and safety data with tenofovir DF treatment in nucleosid(t)e-naive, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Thirty-one patients (11 females, 20 males) received 245 mg tenofovir DF per diem. All patients' initial serum hepatitis B virus (HBV) DNA levels were over 2,000 IU/ml. Serum alanine aminotransferase (ALT) levels, HBeAg, hepatitis B e antibodies (anti-HBe), hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (Anti-HBs), HBV DNA, creatinine and urea levels were evaluated at baseline, and at weeks 12, 24, 48 and 96 during therapy. Thirty-one patients completed 96 weeks of treatment. Mean age was 37.6 ± 9.4 years. The initial mean value of ALT was 79 ± 39.9 IU/L. At baseline, mean of fibrosis (Ishak) of liver biopsies was 2.3 ± 0.7. Two of the patients (5.9%) achieved HBV DNA less than 300 copies at week 12 of treatment and 97.1 % at week 96. HBeAg loss was observed in 6.7% of patients. At week 96, HBsAg loss was not observed in any of the patients. Mean ALT at week 48 was 32.7 U/L, at week 96 32.6 U/L. Renal safety was good. Creatinine remained stable. Tenofovir DF was well tolerated and produced potent, continuous viral suppression with increasing HBeAg loss.
- 1 March 2015
- Vol. 23 (1) , 31-5
Tenofovir disoproxil fumarate treatment in HbeAg-positive patients.
Tenofovir disoproxil fumarate (Tenofovir DF) is a nucleotide analogue. This multicentre study reports retrospectively the long-term efficacy and safety data with tenofovir DF treatment in nucleosid(t)e-naive, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Thirty-one patients (11 females, 20 males) received 245 mg tenofovir DF per diem. All patients' initial serum hepatitis B virus (HBV) DNA levels were over 2,000 IU/ml. Serum alanine aminotransferase (ALT) levels, HBeAg, hepatitis B e antibodies (anti-HBe), hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (Anti-HBs), HBV DNA, creatinine and urea levels were evaluated at baseline, and at weeks 12, 24, 48 and 96 during therapy. Thirty-one patients completed 96 weeks of treatment. Mean age was 37.6 ± 9.4 years. The initial mean value of ALT was 79 ± 39.9 IU/L. At baseline, mean of fibrosis (Ishak) of liver biopsies was 2.3 ± 0.7. Two of the patients (5.9%) achieved HBV DNA less than 300 copies at week 12 of treatment and 97.1 % at week 96. HBeAg loss was observed in 6.7% of patients. At week 96, HBsAg loss was not observed in any of the patients. Mean ALT at week 48 was 32.7 U/L, at week 96 32.6 U/L. Renal safety was good. Creatinine remained stable. Tenofovir DF was well tolerated and produced potent, continuous viral suppression with increasing HBeAg loss.
- 1 March 2014
- Vol. 53 (1) , 31-6
Four-year study of entecavir efficacy and safety in nucleos(t)ide-naïve HBeAg positive chronic hepatitis B patients.
Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naïve HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4 +/- 41.5 IU/L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA < 300 copies; at month 48, 90% of patients had HBV DNA < 50 IU/mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.
- 1 March 2014
- Vol. 53 (1) , 31-6
Four-year study of entecavir efficacy and safety in nucleos(t)ide-naïve HBeAg positive chronic hepatitis B patients.
Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naïve HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4 +/- 41.5 IU/L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA < 300 copies; at month 48, 90% of patients had HBV DNA < 50 IU/mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.
- 1 February 2014
- Vol. 11 (1) , 94-8
The characteristics of patients with chronic hepatitis B in Turkey.
To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.
- 1 February 2014
- Vol. 11 (1) , 94-8
The characteristics of patients with chronic hepatitis B in Turkey.
To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.
- 1 January 2013
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 33 (5) , 1245-1249
The Prevalence and Epidemiological Characteristics of Hepatitis B Virus and Hepatitis C Virus Coinfection in Turkey
- 1 January 2013
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 33 (5) , 1245-1249
The Prevalence and Epidemiological Characteristics of Hepatitis B Virus and Hepatitis C Virus Coinfection in Turkey
- 1 September 2012
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 25 (1) , 19-23
Liver Histology of Patients with Hepatitis C Virus Infection and Normal Alanine Aminotransferase Levels
- 1 September 2012
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 25 (1) , 19-23
Liver Histology of Patients with Hepatitis C Virus Infection and Normal Alanine Aminotransferase Levels
- 1 October 2011
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 15 (10) , e684-e687
The accuracy and validity of a weekly point-prevalence survey for evaluating the trend of hospital-acquired infections in a university hospital in Turkey
- 1 October 2011
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 15 (10) , e684-e687
The accuracy and validity of a weekly point-prevalence survey for evaluating the trend of hospital-acquired infections in a university hospital in Turkey
- 14 September 2010
- Vol. 14 (3) , 218
Pyogenic liver abscess caused by community-acquired multidrug resistance Pseudomonas aeruginosa.
- 14 September 2010
- Vol. 14 (3) , 218
Pyogenic liver abscess caused by community-acquired multidrug resistance Pseudomonas aeruginosa.